Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

No phase data

Trial Status

Recruiting1

Role Distribution

Other Roles1

Activity Timeline

Clinical Trials (1)

NCT06197581Not ApplicableRecruiting
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Breast Cancer, Familial MaleCDK4/6 InhibitorChemotherapeutic Toxicity+5 more
StudychairStart date: 2024-01-12

Research Network

Collaboration Network

4 collaborators·6 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Shulian Wang, MD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Very Similar
1 trials

Shared therapeutic areas:

Breast Cancer, Familial MaleCDK4/6 InhibitorChemotherapeutic Toxicity+5 more

Worked with same sponsors:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborated on 1 trial
Similarity Score84%

Yirui Zhai, MD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Very Similar
1 trials

Shared therapeutic areas:

Breast Cancer, Familial MaleCDK4/6 InhibitorChemotherapeutic Toxicity+5 more

Worked with same sponsors:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborated on 1 trial
Similarity Score84%

Bo Lan, MD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Very Similar
1 trials

Shared therapeutic areas:

Breast Cancer, Familial MaleCDK4/6 InhibitorChemotherapeutic Toxicity+5 more

Worked with same sponsors:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborated on 1 trial
Similarity Score84%

Lei Li, M.D.

Peking Union Medical College Hospital

Related
46 trials

Shared therapeutic areas:

Immune Checkpoint InhibitorsPoly(ADP-ribose) Polymerase Inhibitors
Similarity Score8%

Hao Feng, MD, Ph.D

Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

Related
1 trials

Shared therapeutic areas:

Radiotherapy; Complications
Similarity Score4%

Ahmed Ashour, PhD

Lecturer in oncology , Faculty of mediciné Alexandria University

Related
1 trials

Shared therapeutic areas:

Chemotherapeutic Toxicity
Similarity Score4%

Hongqing Zhuang, M.D.

Department of Peking University Third Hospital

Related
3 trials

Shared therapeutic areas:

Immune Checkpoint Inhibitors
Similarity Score4%

Xiu-mei Ma, MD

Dept. Radiotherapy, Renji Hospital, School of Medicine, SJTU

Related
1 trials

Shared therapeutic areas:

Radiotherapy; Complications
Similarity Score4%

Laurent Mortier, MD,PhD

University Hospital, Lille

Related
4 trials

Shared therapeutic areas:

Radiotherapy; Complications
Similarity Score4%

Jiajia Chen

Zhejiang University

Related
5 trials

Shared therapeutic areas:

Immune Checkpoint Inhibitors
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT06197581Not ApplicableStudyChair

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Breast Cancer, Familial MaleCDK4/6 InhibitorChemotherapeutic Toxicity+5 more
Recruiting

All 1 trials loaded